VBP1 negatively regulates CHIP and selectively inhibits the activity of hypoxia-inducible factor (HIF)-1α but not HIF-2α. J Biol Chem. 2023:104829..
VCAM-1 hUC-MSCs Exert Considerable Neuroprotection Against Cerebral Infarction in Rats by Suppression of NLRP3-Induced Pyroptosis. Neurochem Res. 2023.
VCFshiny: an R/Shiny application for interactively analyzing and visualizing genetic variants. Bioinform Adv. 2023;3(1):vbad107.
VdTps2 modulates plant colonization and symptom development in . Mol Plant Microbe Interact. 2023..
Vedolizumab for children with intestinal graft-versus-host disease: a case report and literature review. Int J Hematol. 2023.
VEGF Expression in Umbilical Cord MSC Depends on the Patient's Health, the Week of Pregnancy in Which the Delivery Took Place, and the Body Weight of the Newborn - Preliminary Report. Stem Cells Cloning. 2023;16:5-18.
VEGF overexpressed mesoangioblasts enhance urethral and vaginal recovery following simulated vaginal birth in rats. Sci Rep. 2023;13(1):8622.
VEGF Secretion Drives Bone Formation in Classical MAP2K1+ Melorheostosis. J Bone Miner Res. 2023..
VEGF-A in serum protects against memory impairment in APP/PS1 transgenic mice by blocking neutrophil infiltration. Mol Psychiatry. 2023.
Veliparib (ABT-888), a PARP inhibitor potentiates the cytotoxic activity of 5-fluorouracil by inhibiting MMR pathway through deregulation of MSH6 in colorectal cancer stem cells. Expert Opin Ther Targets. 2023..
Vemurafenib activates the sonic hedgehog pathway and promotes thyroid cancer stem cell self-renewal. Endocr Relat Cancer. 2023..
A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure. Br J Haematol. 2023.
Venetoclax and Azacitidine Treatment in Relapsed Acute Myeloid Leukemia After Hematopoietic Stem Cell Transplantation: A Cohort Study in a Tertiary Center Real-World Setting. Turk J Haematol. 2023..
Venetoclax and dinaciclib elicit synergistic preclinical efficacy against hypodiploid acute lymphoblastic leukemia. Haematologica. 2023.
Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States. Ann Hematol. 2023.
Venetoclax with CAG regimen for early T-cell precursor acute lymphoblastic leukemia: a case report and literature review. Int J Hematol. 2023..
Venetoclax-azacitidine as salvage therapy for relapsed mixed phenotype acute leukemia after a second allogeneic hematopoietic stem cell transplantation: a case report. Blood Res. 2023..
[Venetoclax-based salvage in multiple myeloma with (11;14) translocation after suboptimal response to first-line therapy]. Orv Hetil. 2023;164(23):894-899..
Venetoclax-based therapy for relapsed or refractory acute myeloid leukaemia following intensive induction chemotherapy. Eur J Haematol. 2023..
Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting. Exp Hematol Oncol. 2023;12(1):57.
Venetoclax-based therapy in treatment-naïve and relapsed/refractory acute myeloid leukemia. Leuk Res. 2023;135:107407..
Venetoclax-based Treatment as Frontline Therapy for Chronic Lymphocytic Leukemia. Hematol Oncol Stem Cell Ther. 2023;16(4):346-350..
Venoarterial Extracorporeal Membrane Oxygenation After Autologous Stem Cell Transplantation With Pancytopenia: JACC Patient Care Pathways. J Am Coll Cardiol. 2023..
Venous thromboembolism in hematopoietic stem cell transplantation: A narrative review. Thromb Res. 2023;226:141-149..